Pharmacokinetic-Pharmacodynamic Analyses for Efficacy of Ceftaroline Fosamil in Patients with Community-Acquired Bacterial Pneumonia

被引：12

作者：

Bhavnani, Sujata M. ^{[1
]}

Hammel, Jeffrey P. ^{[1
]}

Van Wart, Scott A. ^{[1
]}

Rubino, Christopher M. ^{[1
]}

Reynolds, Daniel K. ^{[1
]}

Forrest, Alan ^{[1
]}

Khariton, Tatiana ^{[2
]}

Friedland, H. David ^{[3
]}

Riccobene, Todd A. ^{[2
]}

Ambrose, Paul G. ^{[1
]}

机构：

[1] Inst Clin Pharmacodynam, Latham, NY USA

[2] Forest Res Inst Inc, Jersey City, NJ USA

[3] Cerexa Inc, Oakland, CA USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2013年 / 57卷 / 12期

关键词：

D O I：

10.1128/AAC.01748-13

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Pharmacokinetic-pharmacodynamic (PK-PD) analyses for efficacy using phase III trial data from patients treated with a ceftaroline fosamil dosing regimen of 600 mg intravenously (i.v.) every 12 h (q12h) for 5 to 7 days for community-acquired bacterial pneumonia (CABP) were conducted. High clinical and microbiological success rates (84.7 and 86.3%, respectively) and percentages of time during the dosing interval that free-drug steady-state concentrations remained above the MIC (f%T> MIC) (98.4% had f%T> MIC values of >= 63.3) were observed among 124 microbiologically evaluable patients. As a result, significant PK-PD relationships could not be identified. These data provide support for the use of a ceftaroline fosamil dosing regimen of 600 mg i.v. q12h to treat patients with CABP.

引用

页码：6348 / 6350

页数：3

共 50 条

[1] Ceftaroline fosamil for community-acquired pneumonia Reply
Zhong, Nan Shan
Sun, Tieying
Wilson, David
Melnick, David
[J]. LANCET INFECTIOUS DISEASES, 2015, 15 (09): : 999 - 1000
[2] Pharmacokinetic-Pharmacodynamic Analysis for Efficacy of Ceftaroline Fosamil in Patients with Acute Bacterial Skin and Skin Structure Infections
Bhavnani, Sujata M.
Hammel, Jeffrey P.
van Wart, Scott A.
Rubino, Christopher M.
Reynolds, Daniel K.
Forrest, Alan
Drusano, George L.
Khariton, Tatiana
Friedland, David
Riccobene, Todd A.
Ambrose, Paul G.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (01) : 372 - 380
[3] Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil
Li, Jianguo
Das, Shampa
Zhou, Diansong
Al-Huniti, Nidal
[J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (05): : 682 - 694
[4] Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit
Maggiore, Christy
Vazquez, Jose A.
Guervil, David J.
Ramani, Ananthakrishnan
Jandourek, Alena
Cole, Phillip
Friedland, H. David
[J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 557 - 563
[5] Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection
Casapao, Anthony M.
Steed, Molly E.
Levine, Donald P.
Rybak, Michael J.
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (08) : 1177 - 1186
[6] Ceftaroline Fosamil For The Treatment Of Community-Acquired Bacterial Pneumonia In The Elderly: Capture Study Experience
Udeani, G.
Evans, J.
Cole, P.
Smith, A.
Friedland, H. D.
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
[7] Ceftaroline Fosamil in the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections
Thomas P. Lodise
Donald E. Low
[J]. Drugs, 2012, 72 : 1473 - 1493
[8] Ceftaroline Fosamil in the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections
Lodise, Thomas P.
Low, Donald E.
[J]. DRUGS, 2012, 72 (11) : 1473 - 1493
[9] Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain
Torres, Antoni
Bassetti, Matteo
Welte, Tobias
Rivolo, Simone
Remak, Edit
Peral, Carmen
Charbonneau, Claudie
Hammond, Jennifer
Ansari, Wajeeha
Grau, Santiago
[J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (02) : 148 - 155
[10] Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE
Carreno J.J.
Lodise T.P.
[J]. Infectious Diseases and Therapy, 2014, 3 (2) : 123 - 132

← 1 2 3 4 5 →